Claim Interpretation at the EPO – The Case of G1/24

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Claim Interpretation at the EPO – The Case of G1/24

Sponsored by

23Murgitroyd..png

Stephane Antoine of Murgitroyd explores the implications of the G1/24 case and highlights the EPO's referral mechanisms for addressing legal interpretations and resolving inconsistencies within patent law.

There are a number of mechanisms for having a point of law decided by the Enlarged Board of Appeal at the EPO. One of these is through a referral from a Board of Appeal in accordance with Art 112(1)(a) EPC. This provides a mechanism for referral if:

  • The referring Board believes that a decision requires a clarification of a point of law of fundamental importance.

  • The referring Board identifies a divergence in the case law and needs the Enlarged Board to resolve the conflicting decisions.

This route typically arises in appeal cases when the Board of Appeal is confronted with a legal question that needs authoritative interpretation, or when case law has developed inconsistently. 

Such a situation has recently arisen in case T439/22 where a Technical Board of Appeal has referred points of law to the Enlarged Board of Appeal by interlocutory decision of 24 June 2024. This interlocutory ruling lies from the decision of an opposition division to maintain the claim of European patent EP3076804 as granted. The case number is now referenced as G1/24.

Justification for Referral

The Technical Board of Appeal acknowledges that the outcome of the underlying case appears to hinge on whether the term “gathered sheet” of the claim is given its usual meaning in the art, or whether the same term is read broadly in view of the description. While examining the issue of how the claim should be interpreted for the purpose of assessing patentability, the Technical Board of Appeal identified diverging lines of case law of the European Patent Office.

In view of ensuring a uniform and harmonised application of the law, and in light of the above referenced second mechanism for seeking guidance, the Board of Appeal referred the following three questions to the Enlarged Board of Appeal.

1. Is Article 69 (1), second sentence EPC and Article 1 of the Protocol on the Interpretation of Article 69 EPC to be applied to the interpretation of patent claims when assessing the patentability of an invention under Articles 52 to 57 EPC?

2. May the description and figures be consulted when interpreting the claims to assess patentability and, if so, may this be done generally or only if the person skilled in the art finds a claim to be unclear or ambiguous when read in isolation?

3. May a definition or similar information on a term used in the claims which is explicitly given in the description be disregarded when interpreting the claims to assess patentability and, if so, under what conditions?

These questions are fundamental as the claims of a patent determine the extent of protection, and it is encouraging that the Enlarged Board have decided that the referral is admissible and will be heard. In this regard we understand that it has recently appointed members to deal with this case.

 

Latest Updates

The EPO announced that it is awaiting the decision of the Enlarged Board of Appeal, and that it will immediately implement its findings in the practice of examining and opposition divisions. For the time being, however, examination and opposition proceedings will continue, per the Communication from the EPO:

“Considering the need for legal certainty, ensuring the functioning of the EPO and the interests of all stakeholders, the President has decided that proceedings in examination and opposition should continue while the referral is pending. Examining and opposition divisions will therefore continue to apply the practice set out in the Guidelines for Examination in the EPO, according to which they will, so far as possible, require a claim to be amended such that, in cases where the description gives a specific meaning to words used in the claims, the meaning is clear from the wording of the claim alone..”

What this means for now

It is not unusual for the EPO to elect to stay proceedings on pending applications where there is a referral to the Enlarged Board that may affect the ultimate decision on these pending applications. This case is different, in that the EPO have effectively stated that it is business as usual. We have no visibility as to when the Enlarged Board will come to an ultimate decision, but will of course update here when we hear further.

more from across site and SHARED ros bottom lb

More from across our site

Fresh off a string of ITC victories, Latham has recruited Baker Botts’ ITC leader Lisa Kattan, adding another prominent name to one of the market's busiest ITC practices
The firm hopes its recent Düsseldorf expansion and UK partner hire will strengthen its offering as it looks to an integrated model to boost UPC capabilities
Stephenson Harwood’s trademark prosecution push and patent ambitions could complement Taylor Wessing’s remaining but depleted European IP strength following its UK arm’s departure
Gerben IP’s first woman partner, Sophie Edbrooke, explains how boutique life allowed her to broaden her expertise, take on leadership responsibilities and carve out a route to the top
INTA has a right to protect its Annual Meeting, but making it harder for others to hold similar events risks leaving delegates with a bigger travel bill
The firm says it hopes to capture patent litigation work in Texas by arming itself with experienced trial lawyers with venue expertise
Ken Iijima's arrival continues a trend of ex-Pizzeys practitioners joining RnB IP, whose co-founder says independent ownership and a lucrative compensation model have become attractive in a consolidating market
McDermott Will & Schulte lawyers explore why the UPC is seeing rapid adoption by medtech for fast-moving disputes, while pharma and biotech take a cautious, selective approach over revocation risks
IP firms may be growing more comfortable with external capital, but uncertainty over who could ultimately own the business is complicating the investment pitch
The former Western District of Texas judge addresses perceptions of his courtroom, reveals what comes next as he returns to practice at A&O Shearman and explains why marathon running is ‘cathartic’
Gift this article